Herb-drug interactions in oncology

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 354-355

  Goey, A K L ^a   Beijnen, J H ^b,c   Schellens, J H M ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; DOCETAXEL; ECHINACEA PURPUREA EXTRACT; FUROCOUMARIN; GARLIC EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; SILYBUM MARIANUM EXTRACT; TOPOTECAN;

ALTERNATIVE MEDICINE; CHEMOTHERAPY; CHINESE MEDICINE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HUMAN; PHYTOCHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SHORT SURVEY; TRADITIONAL MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPLEMENTARY THERAPIES; HERB-DRUG INTERACTIONS; HUMANS; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 84897893846     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.18     Document Type: Short Survey

References (4)

1. Davis, E.L et al. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: A systematic review. Oncologist 17, 1475-1481 (2012.
2. Tsai, H.H. et al. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: A systematic literature review. Int. J. Clin. Pract. 66, 1056-1078 (2012.
3. Goey, A.K. et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat. Rev. 39, 773-783 (2013.
4. Kummar, S. et al. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 10, 85-96 (2011.